A Study to Test the Combination of Two Different Kinds of Medications for the Treatment of Diabetes

Summary

Test the safety, tolerability and improvement of blood sugar control with combination therapy in individuals with Type 2 Diabetes.

Timeline

Start

2009-02

Primary completion

2010-05

Completion

2010-05

Outcome

Missed primary endpoint

registry LEAST_SQUARES_MEAN LY2428757 Plus TT223 3mg: -0.08 (Standard Error 0.163) percent glycosylated hemoglobin (HbA1c) NCT00853151 ↗

registry analysis (superiority or other test); LY2428757 Plus TT223 3mg vs LY2428757 Plus TT223 Placebo; p = 0.623; Mixed Models Analysis; NCT00853151 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LY2428757	Unknown	14 mg	Subcutaneous
Subject	TT223	Unknown	2 mg	Subcutaneous
Subject	TT223	Unknown	3 mg	Subcutaneous

Indications